Zacks Investment Research upgraded Insmed Incorporated (NASDAQ:INSM) to Hold in a report released today.
- Updated: October 1, 2016
Having a price of $13.94, Insmed Incorporated (NASDAQ:INSM) traded 4.16% higher on the day. With the last stock price up 20.18% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Insmed Incorporated has recorded a 50-day average of $13.63 and a two hundred day average of $12.08. Volume of trade was down over the average, with 271,004 shares of INSM changing hands under the typical 319,445
Zacks Investment Research has upgraded Insmed Incorporated (NASDAQ:INSM) to Hold in a statement released on 9/29/2016.
Recent Performance Chart
Insmed Incorporated has 52 week low of $9.02 and a 52 week high of $21.14 and has a market capitalization of $0.
A total of 8 brokerages have issued a ratings update on Insmed Incorporated. One brokerage rating the company a strong buy, 4 firms rating the stock a buy, 2 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 equity analysts rating the company a sell with a one year target of $23.63.
More About Insmed Incorporated (NASDAQ:INSM)
Insmed Incorporated is a biopharmaceutical company. The Company operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases. The Company's lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. The Company's earlier stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil, a vasodilator of pulmonary arterial vascular beds. The Company is conducting a global Phase III clinical study of ARIKAYCE (the 212 or CONVERT study) in adult patients with NTM lung disease caused by Mycobacterium avium complex (MAC), the infective species in NTM lung disease in the United States, Europe and Japan.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.